Hypo-fractionated boost in locally advanced non-small cell lung cancer: temporal distribution of boost fractions

Abstract

To propose new schemas for radiation boosting of primary tumors, in locally advanced non-small cell lung cancers (NSCLC), in conjunction with standard chemoradiotherapy. To investigate the effect of temporal distributions of the boost fractions on tumor control. NSCLC cases, previously treated with 60 Gy in 30 fractions, were retrospectively planned by adding a radiation boost (25 Gy in 5 fractions) to the primary tumor. Several integrated and sequential boosting schedules were considered. Biological doses were calculated for targets and organs at risk (OAR). Tumor control probabilities (TCP) were calculated using an empirical model and a stochastic model that accounts more systematically for tumor growth kinetics and cell kill. For heterogeneous patient populations, the TCPs for different boost schedules ranged from 82% to 84% and from 73% to 74% for integrated and sequential boosting respectively. For individual tumors with specific growth parameters, the TCP varied by up to 19% between the different schedules. The TCP for sequential boosting was expected to be up to 67% lower than front integrated boosting. The gap in TCP between schedules was higher for tumors with higher clonogenic cell numbers, lower radio-sensitivity, shorter doubling times and lower cell loss. The proposed boosting schemas are dosimetrically feasible and biologically effective. We suggest that the boosts are most effective when given during the first week of treatment and least effective when given sequentially after the end of treatment. The effect of boost scheduling and the effectiveness of front boosting are expected to be most significant for tumors with high clonogenic cell numbers, fast growing rates, low cell loss and low radio-sensitivity. Ultimately, animal studies and clinical trials, guided by biology modeling as presented in the present work, will be needed to verify the effectiveness of fine tuning temporal distributions of radiotherapy fractions.

Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy

“…Definitive radiotherapy combined with chemotherapy remains the main part of treatment for patients with unresectable locally advanced non-small cell lung cancer (LANS CLC) [1,2]. Hypofractionated radiotherapy (HRT) has been demonstrated as an effective approach for dose escalation [3,4]. The use of HRT is still challenging due to the close distance of target and organs at risk (OAR) in LANSCLC.…”

Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy

“…De nitive radiotherapy combined with chemotherapy remains the main part of treatment for patients with unresectable locally advanced non-small cell lung cancer (LANSCLC) [1,2]. Hypofractionated radiotherapy (HRT) has been demonstrated as an effective approach for dose escalation [3,4]. The use of HRT is still challenging due to the close distance of target and organs at risk (OAR) in LANSCLC.…”